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Abstract
Purpose Cancer-related fatigue (CRF) negatively affects the lives of childhood, adolescent, and young adult (CAYA) cancer
survivors. We aimed to provide an evidence-based clinical practice guideline (CPG) with internationally harmonized CRF
surveillance recommendations for CAYA cancer survivors diagnosed < 30 years.
Methods This CPGwas developed by a multidisciplinary panel under the umbrella of the International Late Effects of Childhood
Cancer Guideline Harmonization Group. After evaluating concordances and discordances of four existing CPGs, we performed
systematic literature searches. We screened articles for eligibility, assessed quality, extracted, and summarized the data from
included articles. We formulated recommendations based on the evidence and clinical judgment.
Results Of 3647 articles identified, 70 articles from 14 countries were included. The prevalence of CRF in CAYA cancer
survivors ranged from 10–85%. We recommend that healthcare providers are aware of the risk of CRF, implement regular
screening with validated measures, and recommend effective interventions to fatigued survivors.
Conclusions A considerable proportion of CAYA cancer survivors suffers from CRF even years after the end of treatment.
Implications for Cancer Survivors We recommend that healthcare providers adopt regular screening to detect and treat CRF early
and positively influence survivors’ health and quality of life.
Keywords Survivors . Childhood, adolescent, and young adult cancer . Surveillance . Late effects . Cancer-related fatigue .
Evidence-based guidelines
Introduction
Thanks to advances in treatment, long-term survival of child-
hood, adolescent, and young adult (CAYA) cancers has im-
proved remarkably over the past decades [1–3]. As a result,
the population of CAYA cancer survivors is increasing [4].
However, most survivors experience late effects from cancer
and its treatment, such as cardiovascular disease, renal dys-
function, endocrinopathies, impaired cognitive function, poor
mental health, and musculoskeletal problems [4–7].
Cancer-related fatigue is a well-known problem during the
active treatment phase of cancer but can also be a frequent
problem for survivors many years after completion of therapy
[8, 9]. The National Comprehensive Cancer Network of the
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USA defined cancer-related fatigue as “a distressing, persis-
tent, subjective sense of physical, emotional and/or cognitive
tiredness or exhaustion related to cancer or cancer treatment
that is not proportional to recent activity and interferes with
usual functioning” [10]. In survivors of adult cancers, about
30% experience cancer-related fatigue even years after com-
pletion of treatment [11, 12]. For CAYA cancer survivors, the
literature on the prevalence of cancer-related fatigue (hereafter
referred to as fatigue) is contradictory. A number of studies
have reported a high prevalence of fatigue in CAYA cancer
survivors [13–15], but other studies have observed prevalence
rates or fatigue levels comparable to controls [16, 17]. Fatigue
has a negative impact on many aspects of CAYA cancer sur-
vivors’ lives, such as personal relationships, school or work,
and activities of daily life, and is associated with lower self-
reported quality of life [9, 14, 18].
Clinical practice guidelines (CPG) could help improve con-
sistency of care, evidence-based healthcare delivery, and thus
health outcomes and quality of life in survivors [19, 20]. This
is especially important as, to date, long-term follow-up
(LTFU) for CAYA cancer survivors is not always well orga-
nized and few pediatric oncology institutions offer LTFU to
adult survivors of CAYA cancers [21]. As many CAYA can-
cer survivors are followed by healthcare providers outside the
pediatric oncology setting [22], CPGs can help to inform
healthcare providers, as well as survivors, about cancer- and
treatment-related risks such as fatigue.
In survivors of adult cancers, regular screening for fatigue
is recommended [23, 24]. For CAYA cancer survivors, differ-
ent groups in North America and Europe have developed
LTFU CPGs to promote early detection of potential late ef-
fects [25–28]. However, these guidelines were developed in-
dependently and differ regarding their recommendations. This
can cause uncertainty about which CPG to use in clinical
practice and could impede the implementation of a CPG for
LTFU of CAYA cancer survivors. Therefore, the International
Late Effects of Childhood Cancer Guideline Harmonization
Group (IGHG) was founded to harmonize CPGs for CAYA
cancer survivors [29]. As the psychological late effects group
of the IGHG, we aimed to harmonize the recommendations
for fatigue surveillance in CAYA cancer survivors diagnosed
before the age of 30.
Methods
To develop this CPG, we utilized the international guideline
harmonization methodology previously described in detail by
Kremer et al. [29]. A multidisciplinary international group of
14 experts in pediatric oncology, radiation oncology, psychol-
ogy, physiotherapy, epidemiology, and guideline methodolo-
gy prepared the fatigue surveillance recommendations. The
final recommendations were discussed with a wider group of
23 additional experts from 10 countries and reviewed by four
patient stakeholders (Table S3).
Comparison of existing guidelines
Our group of experts first evaluated concordances and discor-
dances among the existing CPGs from the Children’s
Oncology Group (COG) [25], the Dutch Childhood
Oncology Group (DCOG) [26], the Scottish Intercollegiate
Guidelines Network (SIGN) [27], and the United Kingdom
Children’s Cancer Study Group Late Effects Group
(UKCCLG) [28] regarding fatigue surveillance recommenda-
tions. In case of discordance between the CPGs, we formulat-
ed clinical questions to achieve consensus. The clinical ques-
tions addressed five key issues: (1) Who needs surveillance?
(2) At what age or time from exposure should surveillance be
performed? (3) At what frequency should surveillance be per-
formed? (4) What surveillance modality should be used? and
(5) What should be done when abnormalities are found?
Search strategy and selection criteria
Systematic literature searches in MEDLINE (through
PubMed), Web of Science, PsycInfo, and Scopus were
performed in February 2016 and the search in
MEDLINE was updated in March 2019 to identify all
available evidence. The search terms “childhood cancer”,
“survivors”, “late effects”, and “fatigue” with synonyms
and variations were used to search the databases (detailed
search s t ra tegies provided in Tables S4a-S4c) .
Additionally, all reference lists of included articles were
hand searched (by SC). We included only papers on
humans, published in English, and published between
January 1990 and March 18, 2019. Studies published after
March 18, 2019 were not included in this CPG. If there
was no evidence available for CAYA cancer survivors,
we carefully extrapolated evidence from survivors of
adult cancers. This evidence was identified by using the
same search strategy but by replacing the “childhood can-
cer” term with “cancer”.
Two authors first independently screened titles and ab-
stracts and excluded irrelevant articles (SC, KR, HCL,
JJL, AVM, KS, and GM participated in the title/abstract
screening). In a second step, two authors independently
assessed the eligibility of the full-text articles (SC, KR,
HCL, JJL, AVM, KS, and GM participated in the full-text
screening). Inclusion criteria were (1) typical childhood,
adolescent, or young adult cancer diagnosis; (2) ≥ 75% of
study participants were < 30 years at cancer diagnosis; (3)
survivors (≥ 50% of study participants were ≥ 2 years
from diagnosis); (4) sample size ≥ 20 participants (de-
tailed inclusion and exclusion criteria in Table S5).
Throughout this manuscript, “survivor” is, therefore,
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defined as being at least 2 years since diagnosis. In case
of a disagreement between the two authors, a third author
helped finding consensus regarding inclusion or exclusion
of the article (KS or GM). Next, we extracted relevant
information of the articles into evidence tables. One arti-
cle could address more than one clinical question.
Corresponding authors were contacted in the event of
missing primary data. We assessed the quality of the in-
cluded articles by evidence-based methods provided by
the Cochrane Childhood Cancer (Table S6). For every
clinical question, we formulated and graded a conclusion
of evidence based on an adapted version of the Grading
of Recommendations Assessment Development and
Evaluation criteria (GRADE; Table S7) [29, 30].
Translating evidence into recommendations
Recommendations were based on consideration of the ev-
idence, costs, benefits versus harms of the surveillance
intervention, the need to maintain the flexibility of appli-
cation across different healthcare systems, and clinical
judgment. Decisions were made through group discussion
and consensus, and final recommendations were supported
unanimously. The strength of the fatigue recommendations
was graded according to published evidence-based
methods (Table S8) [31]. The harmonized fatigue surveil-
lance recommendations were discussed with a wider group
of additional 23 experts (Table S3) from 10 countries via
teleconference and critically appraised by four survivor
representatives (Table S3) via electronic communications.
We used the feedback from these discussions for the final-
ization of the recommendations. The recommendations
will be updated within 5 years.
Results
Comparing the four existing surveillance recommendations
for fatigue, we found they were discordant in all areas
(Table S9). Based on the discordances, nine clinical questions
were formulated to investigate the evidence in more detail
(Table S10). The evidence tables (Table S11) and detailed
conclusions of evidence (Table S12) are presented as
Supplementary Material.
Of 3647 studies identified, 530 full texts were screened and
70 articles were eligible for the fatigue surveillance recom-
mendations (Fig. S1), with a total sample of n = 11,628
CAYA cancer survivors. One CPG and four systematic re-
views were included. The 65 original studies were conducted
in 14 different countries in Asia (12 studies), Europe (21 stud-
ies), North America (30 studies), and South America (two
studies). The conclusions of evidence and the recommenda-
tions are presented in Tables 1 and 2.
Who needs surveillance?
Evidence on the risk of fatigue
The existing CPGs were discordant as only two specified the
population at risk (“all survivors”), [25, 26] and only one
surveillance recommendation identified risk factors for fatigue
in CAYA cancer survivors (Table S9) [25].
There is evidence that CAYA cancer survivors are at
risk for fatigue (level A; Table 1) [13–15, 17, 18,
32–54]. We found 28 articles (24 studies) that reported
the prevalence of fatigue in CAYA cancer survivors
(Table S2) [13–15, 17, 18, 32–54]. Prevalence of fa-
tigue ranged from 10.2 to 85.0% over all 24 studies
[13–15, 17, 18, 32–37, 39–41, 44–49, 51–54].
Some evidence suggests that there is an increased risk
for fatigue in CAYA cancer survivors compared with
controls (level C; Table 1) [13, 14, 17, 33, 39, 44].
Five studies found that the prevalence of fatigue is
higher in survivors than controls with a difference rang-
ing from 5 to 20% (two were statistically significant at
p < 0.05; Table S2) [13, 14, 33, 39, 44]. One study re-
ported a lower prevalence of fatigue in survivors that
was not significantly different from that of community
norms [17].
Evidence suggests higher levels of fatigue in survi-
vors of CAYA cancer compared with controls (level B;
Table 1) [15, 16, 33, 36, 43, 44, 55–66]. Of 30 articles
(29 studies) describing a level of fatigue in CAYA can-
cer survivors [15, 16, 18, 33, 36, 37, 43, 44, 49, 52, 53,
55–73], ten articles reported the level of fatigue in
CAYA cancer survivors only [18, 37, 49, 52, 53, 68,
69, 71–73], one was a case-control study with non-
fatigued survivors as controls [70], and one used survi-
vors of adult cancers as controls [67]. The other 18
articles compared levels of fatigue in survivors with
healthy controls (Table S2) [15, 16, 33, 36, 43, 44,
55–66]. In twelve of these articles, survivors had statis-
tically significant higher levels of fatigue compared with
that of controls [15, 33, 36, 43, 44, 55, 56, 58, 62,
64–66], whereas two studies reported statistically signif-
icant lower levels of fatigue in survivors compared with
controls [60, 61], and four studies reported no statistical
difference between groups [57, 59, 63] or conflicting
evidence [16].
Evidence on risk factors for fatigue
One existing CPGs identified pulmonary radiation as a major
risk factor for developing fatigue [25]. However, we identified
no studies investigating the risk of fatigue after pulmonary
radiation in CAYA cancer survivors.
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Table 1 Overall conclusions of the evidence
Who needs surveillance?
Prevalence of cancer-related fatigue (CRF) in childhood, adolescent and young adult (CAYA) cancer 
survivors [13-15, 17, 18, 32-54]
CAYA cancer survivors are at risk for CRF with prevalence ranging 
from 10 to 85% Level A [13-15, 17, 18, 32-54]
Increased risk for fatigue in CAYA cancer survivors vs. controls
There was a higher prevalence of CRF in survivors with a difference 
ranging from 5 to 20%
Level C [13, 14, 17, 33, 39, 44]
Levels of CRF in CAYA cancer survivors [15, 16, 18, 33, 36, 37, 43, 44, 49, 52, 53, 55-73]
Higher levels of fatigue in CAYA cancer survivors vs. controls Level B [15, 16, 33, 36, 43, 44, 55-66]
Risk factors for CRF in CAYA cancer survivors [13-18, 41, 42, 45, 50, 53, 60, 61, 68, 70, 73]
Treatment-related risk factors
Unclear risk after CNS/brain irradiation Conflicting evidence [16, 17, 41, 42, 61]
Unknown risk after pulmonary radiation No studies
Increased risk after radiotherapy (not further specified) Level C [15-17, 53, 60]
No significant effect of total body irradiation Level B [41, 61]
No significant effect of chemotherapy Level B [15, 17, 41, 53, 60]
No significant effect of surgery Level B [17, 41]
No significant effect of stem cell transplantation Level B [17, 60]
No significant effect of duration of treatment Level C [16]
No significant effect of treatment era Level C [13]
Clinical risk factors
Increased risk in survivors with psychological distress Level A [13, 15, 16, 50, 53, 70]
Increased risk in survivors with a relapse Level B [17, 18, 45]
Increased risk in survivors with late effects or health problems Level B [16, 17, 50, 53, 60]
Increased risk in survivors who experience pain Level B [18, 42, 50, 70]
Increased risk in survivors with sleep problems Level C [18, 70]
Increased risk in survivors with neuro-cognitive impairment Level C [18]
Increased risk in survivors with higher brain dysfunction Level C [68]
Increased risk in survivors with a heart problem Level C [15, 42]
Increased risk in survivors with exercise-induced symptoms Level C [18]
Increased risk in survivors with lung fibrosis Level C [15]
Increased risk in survivors with higher BMI or obesity Level C [13, 15, 18, 42, 50, 53]
Decreased risk in survivors with better health-related quality of life Level C [60]
Decreased risk with longer time since diagnosis Level C [16, 17, 53, 60, 61]
No significant effect of age at diagnosis Level B [15-17]
No significant effect of primary cancer diagnosis Level B [13, 15-17, 42, 53, 60, 61]
No significant effect of thyroid status Level B [13, 15]
No significant effect of amount of exercise Level B [70, 73]
No significant effect of motility disturbance of limbs Level C [68]
No significant effect of seizures Level C [68]
No significant effect of ocular/vision impairment Level C [68]
No significant effect of endocrine abnormality Level C [68]
No significant effect of cytokine levels Level C [42]
No significant effect of smoking Level C [42]
No significant effect of happiness Level C [60]
Demographic risk factors
Increased risk with older age at follow-up Level B [13, 14, 16, 17, 42, 53, 60, 61]
Increased risk in female survivors Level C [13-17, 41, 42, 50, 53, 60, 61]
Increased risk in unmarried survivors Level C [13-16, 18]
Increased risk in survivors with children Level C [15, 18]
Decreased risk in employed survivors Level B [14-16, 18, 50]
No significant effect of level of education, overall average grade and 
remedial education Level B [13, 14, 16, 60]
No significant effect of household income Level C [17]
No significant effect of ethnicity Level C [17, 53]
No significant effect of receiving social benefits Level C [14]
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We identified 16 studies that evaluated risk factors for fa-
tigue in survivors of CAYA cancers [13–18, 41, 42, 45, 50,
53, 60, 61, 68, 70, 73]. The only treatment-related risk factor
associated with an increased risk for fatigue was any radio-
therapy (level C; Table 1) [15–17, 53, 60]. No significant
associations were found between fatigue and the following
treatment-related risk factors: total body irradiation [41, 61],
chemotherapy [15, 17, 41, 53, 60], surgery [17, 41], stem cell
transplantation [17, 60] (all level B), duration of treatment
[16], and treatment era [13] (both level C).
Table 1 (continued)
At what frequency and for how long should surveillance be performed?
Risk of CRF in CAYA cancer survivors[70, 73]
Unknown latency time to develop CRF No studies
Unknown predictors for change over time No studies
Risk of CRF does not change over time in the majority of survivors. 
However, in some survivors the risk of CRF increases or decreases 
over time. 
Level B [70, 73]
What surveillance modality should be used?
Reliability and validity in CAYA cancer patients and survivors [37, 58, 61, 74-88]
In CAYA cancer patients, the Fatigue Scale-Child (FS-C) and 
Fatigue Scale-Adolescent (FS-A) with its proxy versions (Fatigue 
Scale-Parents, Fatigue Scale-Staff) is a valid and reliable instrument 
to measure CRF.
Level B [58, 74-78]
In CAYA cancer patients and survivors, the PedsQL 
Multidimensional Fatigue Scale (5-7 years, 8-12 years, 13-18 
years, 18-25 years) with its proxy versions (parent versions 2-4 
years, 5-7 years) is a valid and reliable instrument to measure CRF.
Level B [74, 79-81]
In CAYA cancer patients and survivors, the PROMIS Pediatric 
Fatigue measures (short form, and computerized adaptive testing) 
is a valid and reliable instrument to measure CRF.
Level B [82-85]
In CAYA cancer patients and survivors, other measuring instruments, 
such as the Multidimensional Fatigue Inventory, and the Turkish 
Scale for the Assessment of Fatigue in Pediatric Oncology Patients 
(versions 7-12 years, 13-18 years) are valid and reliable instruments 
to measure CRF.
Level C [61, 86-88]
In AYA brain tumor survivors, a single-item screening measure for 
CRF (Fatigue Thermometer) is not able to reliably identify clinically 
significant CRF.
Level C [37]
What should be done if abnormalities are identified?
Effectiveness of CRF interventions in CAYA cancer patients and survivors [36, 89-95]
No studies reported on the effect of individual physiotherapy as an 
intervention for CRF No studies
No studies reported on the effect of a revalidation program as an 
intervention for CRF No studies
Reduction in CRF after a physical activity intervention Level B, existing guideline [36, 92-95]
Reduction in CRF after an education intervention Level B [91, 94]
Reduction in CRF after a cognitive behavioral therapy intervention Level C, existing guideline [89, 95]
Reduction in CRF after an adventure-based training Level C [90]
Reduction in CRF after relaxation and mindfulness interventions Level C, existing guideline [92, 95]
No significant effect of a combined physical activity plus psychosocial 
intervention Level C [92]
The evidence is insufficient about the usefulness and safety of 
pharmacological interventions Existing guideline [95]
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The following clinical risk factors were associated with an
increased risk of fatigue: psychological distress (level A) [13,
15, 16, 50, 53, 70], a relapse [17, 18, 45], late effects or health
problems [16, 17, 50, 53, 60], and pain [18, 42, 50, 70] (all
level B). The following clinical risk factors were associated
with a decreased risk of fatigue: longer time since diagnosis
[16, 17, 53, 60, 61] and better health-related quality of life [60]
(both level C). No significant associations were found be-
tween fatigue and the following clinical risk factors: age at
diagnosis [15–17], primary cancer diagnosis [13, 15–17, 42,
53, 60, 61], thyroid status [13, 15], and amount of exercise
[70, 73] (all level B).
Table 2 Surveillance recommendations for cancer-related fatigue in survivors of childhood, adolescent and young adult cancers (see Fig. 1 for process
of CRF surveillance)
Who needs surveillance?
Healthcare providers and survivors of childhood, adolescent and young adult
(CAYA) cancers should be aware that CAYA cancer survivors are risk for cancer-
related fatiguea (CRF; Level A evidence).
Main risk factors for CRF in CAYA cancer survivors are:
Psychological distress (Level A evidence),
Late effects or health problems, pain, relapse, older age at follow-up (Level B
evidence),
Radiotherapy (Level C evidence).
What surveillance modality should be used and how often should
surveillance be performed?
For all CAYA cancer survivors:
A medical history/anamnesis focused on survivors’ feelings of tiredness and
exhaustion is recommended to be performed regularly (at every long-term follow-
up visit, or at general medical checkups) (expert opinion).
Questions to ask: “Do you get tired easily?”, or ”Are you too tired or exhausted to enjoy the
things you like to do?”
For CAYA cancer survivors with an indication for CRF from medical
history/anamnesis:
Further testing with a validated fatigue measureb is recommended (Level B evidence,
expert opinion).
Screening for underlying medical conditionsc that may cause fatigue is recommended
(expert opinion, existing guidelines)
What should be done if abnormalities are identified?
If CRF is diagnosed with a validated fatigue measure and if no underlying medical
condition is identified:
Referral to a specialist in fatigue (or more generic specialist such as psychologist,
physiotherapist, or other relevant specialist) is recommended for CAYA cancer
survivors (expert opinion).
Interventions that are useful:
o Physical activity (Level B evidence);
o Education about CRF (Level B evidence);
o Relaxation and mindfulness (Level C evidence, existing guidelines);
o Cognitive behavioral therapy (Level C evidence, existing guidelines);
o Adventure-based training (Level C evidence).
a CRF is defined as “a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer
treatment that is not proportional to recent activity and interferes with usual functioning” [10].
b Ideally the PROMIS Pediatric Fatigue measure (http://www.healthmeasures.net/index.php?Itemid=992 [accessed August 29th 2019]) or the PedsQL
Multidimensional Fatigue Scale (https://eprovide.mapi-trust.org/instruments/pediatric-quality-of-life-inventory-multidimensional-fatigue-scale
[accessed August 29th 2019]); see Table S13 for list of all measures validated in CAYA cancer patients and survivors
c e.g., other late effects like cardiac dysfunction, [96] endocrine dysfunction, pulmonary dysfunction, and renal dysfunction (IGHG guidelines under
development); and/or other general causes like anemia, arthritis, neuromuscular complications, pain, fever and/or infection, and nutritional deficiencies
[24, 97] (list not conclusive)
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The following demographic risk factors were associated
with an increased risk for fatigue: older age at follow-up (level
B) [13, 14, 16, 17, 42, 53, 60, 61], female sex [13–17, 41, 42,
50, 53, 60, 61], not being married/in a relationship [13–16,
18], and having children [15, 18] (all level C). Being
employed was associated with a decreased risk for fatigue
(level B) [14–16, 18, 50]. No significant associations were
found between fatigue and the following demographic risk
factors: level of education (level B) [13, 14, 16, 60], house-
hold income [17], ethnicity [17, 53], and receiving social ben-
efits [14] (all level C).
At what age or time from exposure should
surveillance be performed?
Evidence on latency time
The existing CPGs were discordant; only two specified when
surveillance for fatigue should start (2 years after the end of
treatment [25] or at the late effects outpatient clinic [26]). We
found no studies that reported on the latency time to develop
fatigue in survivors of CAYA cancers.
At what frequency should surveillance be performed?
Evidence on change of risk over time
The existing CPGs were discordant as only two specified the
interval for fatigue surveillance (one recommends yearly sur-
veillance [25], the other surveillance every 5 years [26]).
We identified two studies that reported unchanged risk for
fatigue over time in the majority of CAYA cancer survivors
but that fatigue status can change over time in some survivors
(level B) [70, 73]. One study showed that long-term survivors
can be persistently fatigued or persistently non-fatigued but
also that fatigue status can change over time: a median of
2.7 years after the first assessment, 39.6% of former fatigue
cases were no longer fatigued and 18.4% of former non-
fatigue cases became fatigued [70]. The other study showed
that mean levels of fatigue did not change significantly from
end of treatment to 36 months post-therapy [73].
What surveillance modality should be used?
Evidence on validity and reliability of fatigue measures
Only one existing CPG specified a measure that should be
used for fatigue surveillance [26]. More general surveillance
recommendations (screen for an underlying medical condi-
tion, psychosocial assessment) were made by two existing
CPGs [25, 26].
In our systematic search, we found 17 studies and one
systematic review that assessed the psychometric properties
of seven different measures for fatigue in CAYA cancer sur-
vivors [37, 58, 61, 74–88]. Ten studies measured fatigue in
CAYA cancer patients [74, 76–80, 82, 83, 86, 87], five in
CAYA cancer survivors [37, 61, 81, 84, 88], and three in a
mixed patient and survivor population [58, 75, 85]. Five stud-
ies and the systematic review investigated the Fatigue Scales
(Fatigue Scale-Child, Fatigue Scale-Adolescent, and proxy
versions) [58, 74–78], four studies the PROMIS Pediatric
Fatigue Measures [82–85], three studies and the systematic
review the PedsQL Multidimensional Fatigue Scale (Peds
QL MFS) [74, 79–81], and five studies other measures
(Fatigue Thermometer [37], Multidimensional Fatigue
Inventory [88] Turkish Scale for the Assessment of Fatigue
in Pediatric Oncology Patients [86, 87], and 12-item fatigue
questionnaire [61]).
Evidence suggests that the Fatigue Scales, the PROMIS
pediatric fatigue measures, and the PedsQL MFS are valid
and reliable measures to diagnose fatigue in patients and sur-
vivors of CAYA cancers (level B; Table 1) [58, 74–85]. There
is some evidence suggesting other measures, such as the
Turkish Scale for the Assessment of Fatigue in Pediatric
Oncology Patients and a 12-item fatigue questionnaire, are
valid and reliable in measuring fatigue in patients and survi-
vors of CAYA cancers (level C) [61, 86–88]. One study found
that a single-item screening measure for fatigue is not able to
reliably identify clinically significant fatigue in CAYA brain
tumor survivors (level C) [37]. A list of the fatigue measures
validated in patients or survivors of CAYA cancers is provid-
ed in Table S13.
What should be done when abnormalities are found?
Only one existing surveillance recommendation specified
possible interventions for fatigue in CAYA cancer survivors,
namely individual cognitive therapy, a revalidation program,
or individual physiotherapy [26].
We identified no studies reporting on a revalidation pro-
gram or individual physiotherapy in the treatment of fatigue in
CAYA cancer survivors. We found one study that investigat-
ed a cognitive-behavioral intervention in CAYA cancer survi-
vors [89]. Two studies in CAYA cancer survivors [36, 90],
one study in CAYA cancer patients [91], and three systematic
reviews in CAYA cancer patients and survivors [92–94] in-
vestigated effects of other fatigue interventions. In addition,
we identified one CPG on the management of fatigue among
CAYA cancer patients [95].
Evidence suggests that physical activity interventions (e.g.,
aerobic, yoga, or combined) [36, 92–95] and education inter-
ventions lead to a reduction in fatigue in CAYA cancer survi-
vors (both level B; Table 1). Some evidence suggests that
adventure-based training (group activities including rock
climbing and team building games) can improve fatigue in
CAYA cancer survivors (level C) [90]. In addition, some
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evidence suggests that relaxation and mindfulness interven-
tions (e.g., acupressure, massage, mindfulness) resulted in a
reduction in fatigue (level C, existing guideline) [92, 95]. To
date, there is insufficient evidence about the usefulness and
safety of pharmacological fatigue interventions in CAYA can-
cer patients and survivors (existing guidelines) [95].
Translating evidence into recommendations
Based on the evidence and group consensus, the panel recom-
mends that healthcare providers and survivors should be
aware of CAYA cancer survivors’ risk for fatigue (strong
recommendation based on level A evidence; Table 2). The
main risk factors for fatigue in CAYA cancer survivors are
psychological distress, late effects or health problems, pain,
relapse, older age at follow-up, and radiotherapy (strong rec-
ommendation based on levels A–C evidence; Table 2).
Many CAYA cancer survivors are not in regular LTFU
[98–100] but should be screened for fatigue nevertheless. If
survivors are not in LTFU care, they should be screened for
fatigue at general medical checkups. In the case of fatigue,
screening is not expected to be overly burdensome for the
survivors nor are false-positive screening results and subse-
quent examinations. However, screening for fatigue in the
regular LTFU appointment, including potential false-positive
screening results with subsequent examinations and referrals,
could result in slightly higher costs of LTFU care. Based on
the identification of a broad range of risk factors, the knowl-
edge of the high prevalence and high levels of fatigue among
CAYA cancer survivors, and the low burden for survivors, the
expert panel decided to strongly recommend surveillance of
Healthcare providers and survivors should be aware of the risk
for cancer-related fatiguea (CRF).
At every long-term follow-up visit, or at general medical checkups,
all survivors should have a medical history/anamnesis focused on survivors’ feelings of
tiredness and exhaustionb:
Further testing with a validated CRF instrument, ideally
the PROMIS Pediatric Fatigue measurec or the PedsQL
Multidimensional Fatigue Scaled.
Indication for CRF No indication for CRF







Retest for symptoms of
CRF













Indication for CRF No indication for CRF
Fig. 1 Process of screening and interventions for cancer-related fatigue in
survivors of childhood, adolescent, and young adult cancers. The green
color indicates a strong recommendation to do. Superscript letter “a”:
cancer-related fatigue is defined as “a distressing, persistent, subjective
sense of physical, emotional and/or cognitive tiredness or exhaustion
related to cancer or cancer treatment that is not proportional to recent
activity and interferes with usual functioning” [10]. Superscript letter
“b”: questions to ask: “Do you get tired easily?” or “Are you too tired
or exhausted to enjoy the things you like to do?” Superscript letter “c”:
http://www.healthmeasures.net/index.php?Itemid=992 [accessed July 1,
2019]. Superscript letter “d”: https://eprovide.mapi-trust.org/instruments/
pediatric-quality-of-life-inventory-multidimensional-fatigue-scale
[accessed July 1st 2019]. Superscript letter “e”: e.g., other late effects like
cardiac dysfunction, [96] endocrine dysfunction, pulmonary dysfunction,
and renal dysfunction (IGHG guidelines under development); and/or
other general causes like anemia, arthritis, neuromuscular
complications, pain, fever and/or infection, and nutritional deficiencies
[24, 97] (list not conclusive)
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fatigue for all survivors. Based on the uncertainty regarding
the risk of fatigue over time, the panel recommends lifelong
screening for fatigue.
Existing CPGs for fatigue surveillance in survivors of adult
cancers recommend a two-step assessment: first, screen for
fatigue with a numerical rating scale (NRS; 0–10 scale) and
perform further assessment if NRS ≥ 4 [24, 97]. The panel
decided to use a similar approach, but not to use a one-item
screening measure for fatigue, because it may not reliably
identify clinically significant fatigue in survivors of CAYA
cancers [37]. Therefore, we recommend that, for all CAYA
cancer survivors, healthcare providers should perform a med-
ical history/anamnesis focused on the survivor’s feelings of
tiredness and exhaustion at every regular long-term follow-up
visit or at general medical checkups (strong recommendation
based on expert opinion; Table 2). If there is an indication for
the presence of fatigue, the panel recommends further testing
with a validated fatigue measure, ideally with the PROMIS
Pediatric Fatigue Measures or the PedsQL MFS (strong rec-
ommendation based on level B evidence and expert opinion;
Table 2). A description of the surveillance process is presented
in Fig. 1.
We based our screening recommendations on several con-
siderations. First, the measure has to demonstrate validity and
reliability in CAYA cancer patients or survivors. Second, ex-
tensive assessments may not be feasible to implement in clin-
ical practice. Third, to be useful along the cancer survivorship
trajectory of CAYA cancer survivors, it is important that the
measure has versions for different age groups, including a
version for adult survivors. Fourth, the measure needs to be
readily available for healthcare providers. Fifth, the measure
needs to be available in different languages because it will
only be used when available in the country’s language. The
PROMIS Pediatric Fatigue Measure and the PedsQL MFS
represent two assessment measures with these qualities
(Table S13). Both measures are validated and demonstrate
good psychometric properties, both have short versions (10–
18 items), versions for different age groups including adult
survivors (PedsQL MFS-Young Adult and Adult; PROMIS
Fatigue measure), are available online and free of cost for
clinicians, and have been translated into various languages.
There is a spectrum of health problems that can cause fa-
tigue symptoms (e.g., late effects such as cardiac dysfunction
[96], endocrine dysfunction, pulmonary dysfunction, and re-
nal dysfunction (IGHG guidelines under development); and/
or other health problems such as anemia, arthritis, neuromus-
cular complications, pain, fever and/or infection, and nutri-
tional deficiencies) [24, 97]. Therefore, if there is an indication
for the presence of fatigue in a CAYA cancer survivor, the
panel recommends to screen for underlying medical condi-
tions (strong recommendation based expert opinion; Table 2).
If no underlying medical condition is identified, the referral
of fatigued CAYA cancer survivors to a specialist in fatigue
(or a more generic specialist such as psychologist, physiother-
apist, or another relevant specialist) is recommended (strong
recommendation based on expert opinion; Table 2).
Additionally, the panel recommends that all fatigued survivors
should be provided with information about fatigue and strate-
gies for the management of fatigue symptoms. Healthcare
providers should also encourage survivors to engage in inter-
ventions that have been shown to be effective in reducing
fatigue, such as physical activity and adventure-based train-
ing, relaxation and mindfulness interventions, and cognitive
behavioral therapy (strong recommendation based on levels B
and C evidence and existing guidelines; Table 2, Fig. 1).
Discussion
We summarize the harmonized recommendations for fatigue
surveillance in CAYA cancer survivors diagnosed before the
age of 30 years. The recommendations were developed using
scientifically rigorous methods, are based on evidence from
published literature, and are supplemented by expert opinion
for topics with little or no evidence. The recommendations are
intended to standardize and improve the quality of LTFU care
for CAYA cancer survivors and to positively influence fatigue
outcomes in survivors. The panel also aimed to raise aware-
ness about CAYA cancer survivors’ risk of fatigue among
healthcare providers and CAYA cancer survivors and empow-
er survivors to make informed health choices.
Table 3 Gaps in knowledge and future directions for research
• High-quality research on risk of fatigue and risk factors for fatigue in
CAYA cancer survivors using scientifically validated fatigue
measurements (PROMIS Pediatric Fatigue, PedsQL Multidimensional
Fatigue Scale)
• Longitudinal studies characterizing the course of fatigue in CAYA
cancer patients and survivors and indicators for change
• Investigations of the impact of aging and elapsed time from
diagnosis on risk for fatigue
• Investigations evaluating the risk for fatigue after CNS/brain irradiation
• Evaluation of the reliability and validity of a 1-item screening tool for
fatigue in CAYA cancer survivors (mixed diagnoses) and parents of
very young survivors
• Psychometric validation of fatigue measures in adult CAYA cancer
survivors
•Determination of clinically significant thresholds for fatiguemeasures
• High-quality randomized controlled trials with larger samples to assess
the effectiveness of fatigue interventions in CAYA cancer survivors.
• Identify the most effective interventions for different age groups
(pediatric survivors, adolescent survivors, young adult survivors,
adult survivors of CAYA cancers)
• Test safety and effectiveness of pharmacological interventions to
reduce fatigue in CAYA cancer survivors
CAYA, childhood, adolescent, and young adult; CNS, central nervous
system; PROMIS, Patient-Reported Outcome Measure Information
System
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We found that the prevalence of fatigue in survivors of
CAYA cancers varied widely from 10 to 85%. Several factors
explain this variability. First, we included 28 studies from 14
different countries on three continents (America, Europe, and
Asia) with different cultural backgrounds. Then, twelve of the
28 included studies used a tool for assessment of fatigue that
was neither standardized nor validated. The other 16 studies
used seven different measures to determine the prevalence of
fatigue. Additionally, the populations of the included studies
varied considerably regarding sample size, follow-up time,
included primary diagnoses, and age at diagnosis. The use of
so many different assessments for fatigue and heterogeneity in
study populations likely contributed to the large differences in
the prevalence of fatigue in CAYA cancer survivors.
Despite a sizable number of studies that reported risk fac-
tors for fatigue in CAYA cancer survivors, the level of evi-
dence for the recommendations is mainly moderate to low.
We found no studies that investigated the latency time to de-
velop fatigue and only two studies that investigated the clini-
cal course of fatigue in CAYA cancer survivors. Future stud-
ies should focus on high-quality research to investigate the
risk of and risk factors for fatigue in CAYA cancer survivors
using scientifically validated fatigue measures (preferably
PROMIS Pediatric Fatigue Measure or PedsQL MFS) in
CAYA cancer survivors and especially in older adult survi-
vors of CAYA cancers. In addition, longitudinal assessment
of fatigue in CAYA cancer patients and survivors is needed to
identify the change of fatigue patterns over time (Table 3).
Thirteen different measures to assess fatigue were used in
the included studies, and twelve studies used a non-
standardizedmeasure. The use of 25 different measuresmakes
a comparison of study results difficult. To increase compara-
bility across studies, as well as to measure the quality of care
across countries, we highly recommend that researchers and
clinicians use the recommended fatigue measures unless they
need a more specific measure to answer their research ques-
tions. This recommendation is in line with other research that
has proposed that the PROMIS fatigue measures (child and
adult versions) should be adopted as standard measures of
fatigue impact and severity [101].
It would be useful to have a psychometrically sound but
very brief fatigue assessment to assess fatigue as a secondary
outcome and increase the standardization of fatigue surveil-
lance in survivors (Fig. 1). This would reduce the burden
associated with fatigue surveillance and potentially improve
clinician adherence to fatigue surveillance recommendations.
In this regard, the psychometric properties of the Fatigue
Thermometer (a 1-item screening tool) [37] should be tested
in diagnostic groups other than brain tumor survivors
(Table 3). Other barriers for surveillance of fatigue include
not all institutions have a LTFU program or not all survivors
have access to a LTFU program, time constraints during the
follow-up appointments, providers’ lack of awareness that
many CAYA cancer survivors suffer from fatigue, absence
of highly effective treatments for fatigue, and previous contra-
dictory evidence about the prevalence of fatigue in CAYA
cancer survivors. Additionally, defining clinically meaningful
thresholds for fatigue measures would be useful for clinical
practice. Health problems such as fatigue, with unspecific and
subjective symptoms, are difficult to measure objectively; val-
idated clinically, significant thresholds are important to sup-
port health insurance coverage for interventions that remediate
fatigue (Table 3).
When no underlying medical condition is identified, the
panel recommends referring survivors who endorse fatigue
to a specialist in fatigue (Fig. 1). However, not many countries
have specialists for fatigue. Healthcare professionals might
need to refer survivors to more generic specialists, such as
psychologists or physiotherapists. If fatigue specialists are
not available, healthcare professionals should counsel survi-
vors about fatigue and interventions available to manage fa-
tigue symptoms. Referral to a more generic specialist should
be considered if the interventions are not successful in
remediating fatigue, survivors find it difficult to adhere to
the interventions, or need more support and guidance.
Physical activity and adventure-based interventions should
be appropriate for the survivor’s age and physical abilities.
Survivors with a higher risk of injury due to chronic health
problems or deconditioning should be referred to a
physiotherapist for supervised training to assure physical
activity are safely implemented. Depending on the maturity
and cognitive abilities, relaxation and mindfulness
interventions can be useful. Cognitive-behavioral interven-
tions need more resources than the more generic interventions
but should be considered for severely fatigued survivors or if
other interventions are not successful. Pharmacological ap-
proaches (erythropoietin, methylphenidate) should not be rou-
tinely used to manage fatigue in CAYA cancer patients and
survivors [95] and use of supplements such as Paullinia
cupana, ginseng products, or CoQ10 is not recommended in
survivors of adult cancers because of limited effectiveness and
evidence [24]. Supplements should therefore not be routinely
used in CAYA cancer survivors.
To date, only a few studies have assessed the effectiveness
of interventions for fatigue in CAYA cancer patients or survi-
vors in a reasonably large sample [36, 89–94]. A reason for
this might be the lack of information about the mechanisms of
fatigue and that, currently, there exists no gold standard inter-
vention for the treatment of fatigue [102]. Other reasons might
be that AYA cancer survivors can be difficult to reach due to
transitions in care and changes of contact information and
usually, studies including AYA cancer survivors have lower
response rates than other groups [103]. Furthermore, barriers
for screening for CRF might also contribute to the lack of
intervention studies.More high-quality randomized controlled
trials (RCT) are needed to study the effectiveness of the
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physical activity, adventure-based, educational, psychosocial,
relaxation and mindfulness, cognitive behavioral therapy, and
pharmacological interventions in survivors of CAYA cancers
(Table 3). These studies’ focus should lie on identifying the
most effective interventions for different age groups (pediatric
survivors, adolescent survivors, young adult survivors, and
adult survivors of CAYA cancers). Evidence from interven-
tion studies in survivors of adult cancers is expected to be
transferable to young adult cancer survivors and can be used
to guide the design of intervention studies for pediatric and
adolescent cancer survivors. Validated fatigue measures, such
as the PROMIS Pediatric Fatigue Measure or the PedsQL
MFS, should be used to assess CRF in RCTs to reduce bias
and increase the comparability of results.
To facilitate dissemination and implementation of this
CPG, the evidence and recommendations will be presented
directly to clinicians through professional societies and
conferences.
Strengths of this CPG are the multidisciplinary and inter-
national working group involved in the harmonization pro-
cess, the evidence-based approach, and the transparency in
formulating and grading the recommendations. The interna-
tional collaboration means a reduction of duplication of effort
to develop CPGs and brings together knowledge from differ-
ent research fields and medical disciplines. A limitation of the
recommendations is the gap in the literature regarding the risk
of fatigue in survivors over time, and interventions to reduce
fatigue in CAYA cancer survivors, as well as the great vari-
ability of measures used in the included studies. Research to
address these gaps in knowledge should be approached in a
systematic, comprehensive manner by sufficiently large
single-institution studies, or national and international multi-
center collaborative projects.
This surveillance guideline, and the international harmoni-
zation initiative that underpins it, aims to improve health out-
comes by facilitating more consistent LTFU care for CAYA
cancer survivors by improving surveillance, detection, and
treatment of fatigue in survivors, as well as promoting strate-
gically planned ongoing research that will inform future
guideline updates.
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